Now on
A new Orphan Drug Designation to Sirolimus
A new Orphan Drug Designation to Sirolimus
Rare Partners presents a poster on Thalassemia project
Rare Partners presents a poster on Thalassemia project.
US Patent Office has issued a patent covering the use of trimethylangelicin in Cystic Fibrosis
The United States Patent and Trademark Office has issued on March 15th the US Patent number 9283206 covering the use of trimethylangelicin (TMA) as CFTR Corrector in Bronchial Epithelial Cells.
Rare Partners Charity Partner at SuisseGas Milano Marathon 2016.
Rare Partners Charity Partner at SuisseGas Milano Marathon 2016.
Run4Usher, #runandimagetofly with us for Usher Syndrome.
Orphan Drug Designation to Sirolimus
The European Commission grants Orphan Drug Designation to Sirolimus (Rapamycin) for the treatment of beta thalassaemia intermedia and major